E

uropean regulators say that Teva Pharmaceuticals and its Cephalon unit breached antitrust rules by agreeing to delay a cheaper generic version of the Provigil sleep-disorder pill from reaching consumers.

The findings, which are preliminary, refer to the same so-called pay-to-delay arrangement that, two years ago, prompted Teva to pay $1.2 billion to the U.S. Federal Trade Commission to settle allegations that the companies violated antitrust law.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy